Advances in the orthopedic management of osteogenesis imperfecta.

[1]  F. Chang,et al.  Three-dimensional ultrasound in the prenatal diagnosis of osteogenesis imperfecta. , 2012, Taiwanese journal of obstetrics & gynecology.

[2]  M. Lazaretti-Castro,et al.  Safety and efficacy of a 1-year treatment with zoledronic acid compared with pamidronate in children with osteogenesis imperfecta , 2012, Journal of pediatric endocrinology & metabolism : JPEM.

[3]  M. Bell,et al.  Use of the Sheffield telescopic intramedullary rod system for the management of osteogenesis imperfecta: clinical outcomes at an average follow-up of nineteen years. , 2011, The Journal of bone and joint surgery. American volume.

[4]  Raymond Dalgleish,et al.  EMQN best practice guidelines for the laboratory diagnosis of osteogenesis imperfecta , 2011, European Journal of Human Genetics.

[5]  N. Davies,et al.  Experience With the Fassier-Duval Telescopic Rod: First 24 Consecutive Cases With a Minimum of 1-Year Follow-up , 2011, Journal of pediatric orthopedics.

[6]  F. Rauch,et al.  Fassier–Duval femoral rodding in children with osteogenesis imperfecta receiving bisphosphonates: functional outcomes at one year , 2011, Journal of children's orthopaedics.

[7]  A. Hoischen,et al.  Exome sequencing identifies truncating mutations in human SERPINF1 in autosomal-recessive osteogenesis imperfecta. , 2011, American journal of human genetics.

[8]  R. McCall,et al.  Alendronate for the treatment of pediatric osteogenesis imperfecta: a randomized placebo-controlled study. , 2011, The Journal of clinical endocrinology and metabolism.

[9]  R. Sakkers,et al.  Decrease in outpatient department visits and operative interventions due to bisphosphonates in children with osteogenesis imperfecta , 2011, Journal of children's orthopaedics.

[10]  E. Monti,et al.  GH in combination with bisphosphonate treatment in osteogenesis imperfecta. , 2010, European journal of endocrinology.

[11]  P. Lapunzina,et al.  Identification of a frameshift mutation in Osterix in a patient with recessive osteogenesis imperfecta. , 2010, American journal of human genetics.

[12]  P. Byers,et al.  Mutations in the gene encoding the RER protein FKBP65 cause autosomal-recessive osteogenesis imperfecta. , 2010, American journal of human genetics.

[13]  Joseph A. Morgan,et al.  Prenatal Diagnosis and Management of Intrauterine Fracture , 2010, Obstetrical & gynecological survey.

[14]  C. Rotimi,et al.  Lack of cyclophilin B in osteogenesis imperfecta with normal collagen folding. , 2010, The New England journal of medicine.

[15]  P. Byers,et al.  Homozygosity for a missense mutation in SERPINH1, which encodes the collagen chaperone protein HSP47, results in severe recessive osteogenesis imperfecta. , 2010, American journal of human genetics.

[16]  F. Glorieux,et al.  Risedronate in the Treatment of Mild Pediatric Osteogenesis Imperfecta: A Randomized Placebo‐Controlled Study , 2009, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[17]  A. Abdelrahman,et al.  Modified Sofield-Millar operation: less invasive surgery of lower limbs in osteogenesis imperfecta , 2009, International Orthopaedics.

[18]  Hironori Ito,et al.  Bisphosphonate Therapy for Osteogenesis Imperfecta , 2009 .

[19]  L. Samson-Fang,et al.  Effects of bisphosphonates in children with osteogenesis imperfecta: an AACPDM systematic review , 2009, Developmental medicine and child neurology.

[20]  P. Kwok,et al.  Mutation and polymorphism spectrum in osteogenesis imperfecta type II: implications for genotype–phenotype relationships , 2008, Human molecular genetics.

[21]  F. Glorieux,et al.  Consortium for osteogenesis imperfecta mutations in the helical domain of type I collagen: regions rich in lethal mutations align with collagen binding sites for integrins and proteoglycans , 2007, Human mutation.

[22]  R. Engelbert,et al.  Quality of life in children with osteogenesis imperfecta treated with oral bisphosphonates (Olpadronate): a 2-year randomized placebo-controlled trial , 2007, European Journal of Pediatrics.

[23]  C. Tifft,et al.  Prolyl 3-hydroxylase 1 deficiency causes a recessive metabolic bone disorder resembling lethal/severe osteogenesis imperfecta , 2007, Nature Genetics.

[24]  F. Glorieux,et al.  CRTAP Is Required for Prolyl 3- Hydroxylation and Mutations Cause Recessive Osteogenesis Imperfecta , 2006, Cell.

[25]  S. Adami,et al.  Early bisphosphonate treatment in infants with severe osteogenesis imperfecta. , 2006, The Journal of pediatrics.

[26]  Yehia Nour Eldin Tarraf,et al.  Surgery versus surgery plus pamidronate in the management of osteogenesis imperfecta patients: a comparative study , 2006, Journal of pediatric orthopedics. Part B.

[27]  L. Dimeglio,et al.  Two‐Year Clinical Trial of Oral Alendronate Versus Intravenous Pamidronate in Children With Osteogenesis Imperfecta , 2005, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[28]  H. Plotkin,et al.  Bone Healing in Children With Osteogenesis Imperfecta Treated With Bisphosphonates , 2005, Journal of pediatric orthopedics.

[29]  R. Bank,et al.  Phenotypic and molecular characterization of Bruck syndrome (osteogenesis imperfecta with contractures of the large joints) caused by a recessive mutation in PLOD2 , 2004, American journal of medical genetics. Part A.

[30]  F. Glorieux,et al.  Delayed Osteotomy but Not Fracture Healing in Pediatric Osteogenesis Imperfecta Patients Receiving Pamidronate , 2004, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[31]  R. Engelbert,et al.  Skeletal effects and functional outcome with olpadronate in children with osteogenesis imperfecta: a 2-year randomised placebo-controlled study , 2004, The Lancet.

[32]  E. Viora,et al.  Increased nuchal translucency in the first trimester as a sign of osteogenesis imperfecta. , 2002, American journal of medical genetics.

[33]  Miikka Vikkula,et al.  LDL Receptor-Related Protein 5 (LRP5) Affects Bone Accrual and Eye Development , 2001, Cell.

[34]  K. Khoshhal,et al.  Effect of Lower Limb Sofield Procedure on Ambulation in Osteogenesis Imperfecta , 2001, Journal of pediatric orthopedics.

[35]  M. Bell,et al.  Surgical stabilisation of the lower limb in osteogenesis imperfecta using the Sheffield Telescopic Intramedullary Rod System. , 1998, The Journal of bone and joint surgery. British volume.

[36]  L. Ala‐Kokko,et al.  Conformation sensitive gel electrophoresis for simple and accurate detection of mutations: comparison with denaturing gradient gel electrophoresis and nucleotide sequencing. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[37]  C. Mathew,et al.  Osteogenesis imperfecta type III: mutations in the type I collagen structural genes, COL1A1 and COL1A2, are not necessarily responsible. , 1993, Journal of medical genetics.

[38]  M. Bell,et al.  The role of expanding intramedullary rods in osteogenesis imperfecta. , 1989, The Journal of bone and joint surgery. British volume.

[39]  E. Bleck,et al.  Complications of Intramedullary Rods in Osteogenesis Imperfecta: Bailey‐Dubow Rods Versus Nonelongating Rods , 1988, Journal of pediatric orthopedics.

[40]  B. Baljet.  [Willem Vrolik as a teratologist]. , 1984, Nederlands tijdschrift voor geneeskunde.

[41]  W. Sharrard,et al.  Intramedullary rodding with Bailey-Dubow extensible rods in osteogenesis imperfecta. An interim report of results and complications. , 1984, The Journal of bone and joint surgery. British volume.

[42]  J. Hirsch,et al.  Internal deletion in a collagen gene in a perinatal lethal form of osteogenesis imperfecta , 1983, Nature.

[43]  G. Barsh,et al.  Type I osteogenesis imperfecta: a nonfunctional allele for pro alpha 1 (I) chains of type I procollagen. , 1982, Proceedings of the National Academy of Sciences of the United States of America.

[44]  A. Dal Monte,et al.  Osteogenesis imperfecta: results obtained with the Sofield method of surgical treatment. , 1982, Italian journal of orthopaedics and traumatology.

[45]  Peltier Lf.  The classic: congenital osteomalacia. Olaus Jacob Ekman. , 1981 .

[46]  Olaus Jacob Ekman.  The Classic: Congenital Osteomalacia , 1981 .

[47]  R. Bailey.  Further clinical experience with the extensible nail. , 1981, Clinical orthopaedics and related research.

[48]  D. Sillence,et al.  Genetic heterogeneity in osteogenesis imperfecta. , 1979, Journal of medical genetics.

[49]  E. Millar,et al.  Fragmentation, Realignment, and Intramedullary Rod Fixation of Deformities of the Long Bones in Children: A Ten-year Appraisal , 1959 .

[50]  S. Teitelbaum,et al.  Bone collagen aggregation abnormalities in osteogenesis imperfecta , 2006, Calcified Tissue Research.

[51]  B. Baljet.  Aspects of the history of osteogenesis imperfecta (Vrolik's syndrome). , 2002, Annals of anatomy = Anatomischer Anzeiger : official organ of the Anatomische Gesellschaft.

[52]  J. Leong,et al.  The Sofield-Millar operation in osteogenesis imperfecta , 2000 .

[53]  J. Jerosch,et al.  Complications after treatment of patients with osteogenesis imperfecta with a Bailey-Dubow rod , 1998, Archives of Orthopaedic and Trauma Surgery.

[54]  Bailey Rw,et al.  STUDIES OF LONGITUDINAL BONE GROWTH RESULTING IN AN EXTENSIBLE NAIL. , 1963 .